Form 4: Eli Lilly Exec Buys $634K in LLY Stock

Eli Lilly's EVP, CSO, and President of LRL & LLY Imm, Daniel Skovronsky, plans to purchase 1,000 shares of company common stock for approximately $634,405.

Summary

• Daniel Skovronsky, Executive Vice President, Chief Scientific Officer, and President of Lilly Research Laboratories & Lilly Immunology at Eli Lilly & Co (LLY), is set to acquire 1,000 shares of common stock.
• The transaction is scheduled to occur on August 12, 2025, and is made pursuant to a Rule 10b5-1 plan.
• The shares are to be purchased at a weighted average price of $634.405 per share, totaling approximately $634,405.
• Following this planned transaction, Skovronsky will directly own 137,660.112 shares.
• Indirect holdings include 72,359 shares via a trust, 747 shares by spouse, and 2,510 shares by spouse's Spousal Lifetime Access Trust (SLAT).
• On March 10, 2025, Skovronsky's spouse transferred 2,510 shares of Eli Lilly common stock to a SLAT, where the spouse is trustee and the spouse and children are beneficiaries.

Sentiment

Score: 8

Explanation: The significant planned purchase of company stock by a high-level executive indicates strong internal confidence in Eli Lilly's current valuation and future prospects, which is generally viewed positively by the market.

Positives

• A key executive, Daniel Skovronsky, is planning to purchase 1,000 shares of Eli Lilly common stock, indicating strong confidence in the company's future prospects.
• The planned purchase price of $634.405 per share suggests management believes the stock is a good value at current levels.
• The transaction is being made under a Rule 10b5-1 plan, which often signifies a pre-arranged commitment based on a long-term view of the company's value.

Future Outlook

The filing indicates a planned purchase of common stock by Daniel Skovronsky on August 12, 2025, pursuant to a Rule 10b5-1 plan, signaling a pre-arranged commitment to acquire shares.

Related Party Transactions

• Daniel Skovronsky's spouse transferred 2,510 shares of Eli Lilly common stock to a spousal lifetime access trust (SLAT) on March 10, 2025, where the spouse is trustee and the spouse and children are beneficiaries.

Stakeholder Impact

• Shareholders: The planned insider purchase provides a positive signal of management's confidence in the company's future performance and valuation.

Key Dates

Recommendation

The planned acquisition of 1,000 shares by a high-level executive, Daniel Skovronsky, through a Rule 10b5-1 plan, demonstrates a pre-committed belief in Eli Lilly's long-term value and prospects. This insider buying, especially under a structured plan, suggests management views the current stock price as attractive, warranting a 'buy' recommendation.

Keywords

Eli Lilly, LLY, insider trading, stock purchase, Form 4, Daniel Skovronsky, pharmaceutical, biotech, Rule 10b5-1